Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease
At both standard and low budesonide doses, the triple-combination therapy showed a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies First time the benefit of two doses of a fixed triple-combination therapy has been established in a Phase III chronic obstructive pulmonary disease trialAstraZeneca today announced positive results from the Phase III ETHOS trial[ ]for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).